[go: up one dir, main page]

ATE430555T1 - Pharmazeutische zusammensetzungen zur behandlung von asthma - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von asthma

Info

Publication number
ATE430555T1
ATE430555T1 AT02753549T AT02753549T ATE430555T1 AT E430555 T1 ATE430555 T1 AT E430555T1 AT 02753549 T AT02753549 T AT 02753549T AT 02753549 T AT02753549 T AT 02753549T AT E430555 T1 ATE430555 T1 AT E430555T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
treating asthma
asthma
treating
pharmaceutical
Prior art date
Application number
AT02753549T
Other languages
English (en)
Inventor
Joel Sequeira
Stefan Sharpe
John Hart
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE430555(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE430555T1 publication Critical patent/ATE430555T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02753549T 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma ATE430555T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Publications (1)

Publication Number Publication Date
ATE430555T1 true ATE430555T1 (de) 2009-05-15

Family

ID=23224164

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09006110T ATE503461T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma
AT02753549T ATE430555T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09006110T ATE503461T1 (de) 2001-08-28 2002-08-27 Pharmazeutische zusammensetzungen zur behandlung von asthma

Country Status (27)

Country Link
US (3) US20030114428A1 (de)
EP (3) EP1420759B1 (de)
JP (3) JP2005502675A (de)
KR (1) KR100970531B1 (de)
CN (2) CN101856362A (de)
AR (1) AR036358A1 (de)
AT (2) ATE503461T1 (de)
AU (1) AU2002313828B2 (de)
BR (1) BR0212089A (de)
CA (1) CA2457926A1 (de)
CO (1) CO5560551A2 (de)
CY (2) CY1109212T1 (de)
DE (2) DE60232251D1 (de)
DK (2) DK1420759T3 (de)
ES (3) ES2325316T3 (de)
HK (3) HK1060972A1 (de)
HU (1) HUP0401514A3 (de)
MX (1) MXPA04001875A (de)
NO (1) NO20041277L (de)
NZ (1) NZ530987A (de)
PE (1) PE20030390A1 (de)
PL (1) PL209640B1 (de)
PT (2) PT2092935E (de)
SI (2) SI2092935T1 (de)
TW (1) TWI324934B (de)
WO (1) WO2003020253A2 (de)
ZA (1) ZA200401419B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DK1372608T3 (da) * 2001-03-30 2007-12-27 Jagotec Ag Medicinske aerosolformuleringer
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (de) * 2002-08-23 2012-06-27 Schering Corporation Aerosolhaltiger pharmazeutischer Dosierinhalator
ES2388537T3 (es) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Inhalador dosificador que contiene una formulación en suspensión de aerosol
EP1542904B1 (de) * 2002-08-27 2008-01-16 Schering Corporation Verfahren zur herstellung von dosierinhalatorformulierungen
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1925293A3 (de) * 2003-10-20 2010-01-13 Schering Corporation Pharmazeutische Aerosol-Zusammensetzungen
US20050186144A1 (en) * 2004-01-21 2005-08-25 Schering Corporation Treatment methods
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
ATE404186T1 (de) * 2004-10-12 2008-08-15 Generics Uk Ltd Verfahren zur herstellung von suspensionsaerosolformulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
MX2008010353A (es) * 2006-02-09 2009-03-05 Schering Corp Formulaciones farmaceuticas.
JP2010518076A (ja) * 2007-02-09 2010-05-27 シェーリング コーポレイション 安定な医薬エアロゾル製剤
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (de) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung
MX2010007569A (es) * 2008-01-10 2011-03-21 Schering Corp Star Productos farmaceuticos para inhalacion, sistemas y usos.
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP2432531B1 (de) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI707700B (zh) * 2009-05-29 2020-10-21 美商沛爾醫療股份有限公司 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β2腎上腺素受體激動劑之組成物，及相關方法及系統
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
AP3141A (en) 2009-11-25 2015-02-28 Boehringer Ingelheim Int Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
DK2774612T3 (da) * 2009-12-07 2017-11-20 Horizon Orphan Llc 4-Methylpyrazolformuleringer
PH12012501666A1 (en) 2010-02-22 2012-11-05 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate, and a process to make it
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
ES2704465T3 (es) * 2011-10-11 2019-03-18 Chiesi Farm Spa Micropartículas cristalinas de un agonista de beta recubierto con un ácido graso
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP3030298B1 (de) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Vernebler
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
JP6580070B2 (ja) 2014-05-07 2019-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 容器、ネブライザ、及び使用
WO2015169429A2 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Container, indicator device, and nebulizer
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
US9360400B2 (en) 2014-06-30 2016-06-07 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods
ES2869176T3 (es) 2015-12-04 2021-10-25 Mexichem Fluor Sa De Cv Composición farmacéutica
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017156287A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
CA2111002C (en) * 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
IL128714A (en) * 1996-08-29 2003-05-29 Schering Corp Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
GB2359749B (en) * 1998-11-26 2004-05-05 Britannia Pharmaceuticals Ltd Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
CN1406124A (zh) * 2000-01-20 2003-03-26 巴斯利尔药物股份公司 鼻给药的环肽组合物
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
DE60232251D1 (de) 2009-06-18
US20030114428A1 (en) 2003-06-19
WO2003020253A3 (en) 2003-05-22
KR100970531B1 (ko) 2010-07-16
WO2003020253A2 (en) 2003-03-13
EP2319494B1 (de) 2012-06-13
JP2009185075A (ja) 2009-08-20
ES2325316T3 (es) 2009-09-01
ZA200401419B (en) 2005-01-26
CO5560551A2 (es) 2005-09-30
PL368897A1 (en) 2005-04-04
ES2389480T3 (es) 2012-10-26
DE60239648D1 (de) 2011-05-12
CY1111726T1 (el) 2015-10-07
ES2361805T3 (es) 2011-06-22
KR20040031002A (ko) 2004-04-09
NO20041277L (no) 2004-03-26
DK1420759T3 (da) 2009-08-03
CN101856362A (zh) 2010-10-13
CY1109212T1 (el) 2014-07-02
ATE503461T1 (de) 2011-04-15
HK1128428A1 (en) 2009-10-30
EP2319494A1 (de) 2011-05-11
BR0212089A (pt) 2004-08-03
EP1420759B1 (de) 2009-05-06
EP2092935B1 (de) 2011-03-30
JP5170789B2 (ja) 2013-03-27
JP2010138184A (ja) 2010-06-24
HUP0401514A2 (hu) 2004-12-28
TWI324934B (en) 2010-05-21
CN1649568B (zh) 2010-10-27
MXPA04001875A (es) 2004-06-15
SI1420759T1 (sl) 2009-10-31
HUP0401514A3 (en) 2012-08-28
JP2005502675A (ja) 2005-01-27
US20050147565A1 (en) 2005-07-07
CA2457926A1 (en) 2003-03-13
PT1420759E (pt) 2009-06-30
CN1649568A (zh) 2005-08-03
HK1151987A1 (en) 2012-02-17
AU2002313828B2 (en) 2005-09-08
EP1420759A2 (de) 2004-05-26
PE20030390A1 (es) 2003-04-24
US20100143269A1 (en) 2010-06-10
DK2092935T3 (da) 2011-07-18
HK1060972A1 (en) 2004-09-03
AR036358A1 (es) 2004-09-01
EP2092935A1 (de) 2009-08-26
SI2092935T1 (sl) 2011-07-29
NZ530987A (en) 2006-08-31
PT2092935E (pt) 2011-05-31
PL209640B1 (pl) 2011-09-30

Similar Documents

Publication Publication Date Title
ATE503461T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
FI20011478L (fi) Farmaseuttinen koostumus
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
DE60211740D1 (de) Zusammensetzung zur saatgutbehandlung
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
EE200300589A (et) Ravimkoostised
EP1395215A4 (de) Chinoloncarbonsäure-zusammensetzungen und verwandte behandlungsverfahren
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
FI20022128A0 (fi) Farmaseuttinen koostumus
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1420759

Country of ref document: EP